` 600993 (Mayinglong Pharmaceutical Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

M
600993
vs
S
Shanghai Composite

Over the past 12 months, Mayinglong Pharmaceutical Group Co Ltd has underperformed Shanghai Composite, delivering a return of +8% compared to the Shanghai Composite's +14% growth.

Stocks Performance
600993 vs Shanghai Composite

Loading
600993
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
600993 vs Shanghai Composite

Performance Gap Between 600993 and SSEC
HIDDEN
Show

Performance By Year
600993 vs Shanghai Composite

Loading
600993
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Mayinglong Pharmaceutical Group Co Ltd vs Peers

Shanghai Composite
600993
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
12.3B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Mayinglong Pharmaceutical Group Co Ltd Intrinsic Value
HIDDEN
Show
Back to Top